<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210103049933N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-05-24</date_registration>
      <primary_sponsor>Islamic Azad University</primary_sponsor>
      <public_title>The effects of curcumin supplementation along with pilates training in overweight and obese women</public_title>
      <acronym></acronym>
      <scientific_title>The effects of curcumin supplementation along with pilates training on anthropometric indices, liver enzymes and lipid profile in overweight and obese women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-05-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/53903</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Factorial, Purpose: Supportive, Randomization description: Assignment of people in each of the study groups (supplement, placebo, pilates training and supplement, pilates training and placebo) will be done by "Random allocation software" using classified randomized blocking method (block size: 4). In addition, in order to reduce selection bias error, allocation concealment will be used. This will be done by assigning unit codes (two codes A and B) to each person's capsules. In this way, 60 people will be randomly allocated to supplement (n = 15), placebo (n = 15), pilates training and supplement (15), pilates training and placebo (n = 15) groups. In fact, each person will receive a can containing code A or B, and eventually 30 people will receive cans containing code A and 30 people will receive cans containing code B. Also, 30 people in two groups will receive pilates training in addition to supplement or placebo, Blinding description: In the present study, the statistical analyst will be blinded to the study groups. Before starting the study, the cans containing the respective capsules will be coded by a person other than the researcher (this person will not aware of the details of the research) to A and B, so that the type of received capsules in each group will be blinded for researcher. Also, placebo and supplement capsules will be similar in terms of color, shape, size and taste. In addition, cans containing the supplement and placebo will be quite similar.</study_design>
      <phase>3</phase>
      <hc_freetext>Overweight and obesity.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:1) Supplement: one capsule 500 mg/d (450 mg of turmeric rhizome and 50 mg of turmeric extract) for 8 weeks. Intervention 2: Control group: one capsule 500 mg/d containing starch for 8 weeks. Intervention 3: Intervention group: 2) Pilates training (three times/week, 1 hour each time) and supplement one capsule 500 mg/d (450 mg of turmeric rhizome and 50 mg of turmeric extract) for 8 weeks. Intervention 4: Intervention group: 3) Pilates training (three times/week, 1 hour each time) and placebo (one capsule 500 mg/d containing starch) for 8 weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is The person's information will be confidential and the results will be as collective statistics</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>zeynab porasgari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.133, Mehregan Medical Building, Motahari St, Ramsar, Iran</address>
        <city>Ramsar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۴۶۹۱۸۴۶۹۴۰</zip>
        <telephone>+98 911 196 0775</telephone>
        <email>porasgarizeynab@yahoo.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zeynab Porasgari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.133, Mehregan Medical Building, Motahari St, Ramsar, Iran</address>
        <city>Ramsar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۴۶۹۱۸۴۶۹۴۰</zip>
        <telephone>+98 911 196 0775</telephone>
        <email>porasgarizeynab@yahoo.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Willingness to participate in the study
Women between 20 to 50 years old
Body mass index (BMI) between 25 to 35 (kg / m2)</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>50 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Reluctance of patients to participate in the study
Use of other dietary supplements, probiotics and anti-inflammatory drugs
Use of any antioxidant supplements in the last 3 months
Use of immunosuppressive drugs
Following of special diets
Change of diet or decide to lose weight
Pregnancy, lactation
Smokers
Menopause
Having a history of diabetes, cancer, liver, kidney, thyroid and  gastrointestinal diseases
Having surgical operation to weight loss</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E66</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Overweight and obesity</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Lifestyle</i_code>
      <i_code>Placebo</i_code>
      <i_code>Lifestyle</i_code>
      <i_code>Lifestyle</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:1) Supplement: one capsule 500 mg/d (450 mg of turmeric rhizome and 50 mg of turmeric extract) for 8 weeks</i_keyword>
      <i_keyword>Control group: one capsule 500 mg/d containing starch for 8 weeks</i_keyword>
      <i_keyword>Intervention group: 2) Pilates training (three times/week, 1 hour each time) and supplement one capsule 500 mg/d (450 mg of turmeric rhizome and 50 mg of turmeric extract) for 8 weeks</i_keyword>
      <i_keyword>Intervention group: 3) Pilates training (three times/week, 1 hour each time) and placebo (one capsule 500 mg/d containing starch) for 8 weeks</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Weight. Timepoint: Before the intervention and 1 week after the end of intervention. Method of measurement: Seca scale.</prim_outcome>
      <prim_outcome>Body mass index. Timepoint: Before the intervention and 1 week after the end of intervention. Method of measurement: Weight divided by the square of height in meters (kg / m2).</prim_outcome>
      <prim_outcome>Waist circumference. Timepoint: Before the intervention and 1 week after the end of intervention. Method of measurement: Tape metre (cm).</prim_outcome>
      <prim_outcome>Hip circumference. Timepoint: Before the intervention and 1 week after the end of intervention. Method of measurement: Tape metre (cm).</prim_outcome>
      <prim_outcome>Lipid profile (HDL-c, LDL-c, TG, total cholesterol and VLDL). Timepoint: Before the intervention and 1 week after the end of intervention. Method of measurement: Colorimetric enzymatic method (Pars Azmun).</prim_outcome>
      <prim_outcome>Alanine transaminase, Aspartate transaminase and Gamma-glutamyltransferase. Timepoint: Before the intervention and 1 week after the end of intervention. Method of measurement: Colorimetric enzymatic method (Pars Azmun).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Islamic Azad University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-04-20</approval_date>
        <contact_name>Research Ethics Committee of Sport Sciences Research Institute</contact_name>
        <contact_address>Velayat University Complex, Shahid Sohani St., Army Blvd, Imam Ali highway, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
